-
Product Insights
NewLikelihood of Approval Analysis for Pulmonary Fibrosis
Overview How likely is it that the drugs in Pulmonary Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Fibrosis Overview Pulmonary fibrosis is a lung disease that causes lung...
-
Product Insights
NewLikelihood of Approval Analysis for Pulmonary Tuberculosis
Overview How likely is it that the drugs in Pulmonary Tuberculosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Tuberculosis Overview Pulmonary tuberculosis (TB) is an infectious respiratory disease caused...
-
Product Insights
NewLikelihood of Approval Analysis for Pulmonary Embolism
Overview How likely is it that the drugs in Pulmonary Embolism will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Embolism Overview Pulmonary embolism is the sudden blockage of a major...
-
Product Insights
NewLikelihood of Approval Analysis for Pulmonary Hypertension
Overview How likely is it that the drugs in Pulmonary Hypertension will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Hypertension Overview Pulmonary hypertension (PH) is a rare condition marked by...
-
Product Insights
NewLikelihood of Approval Analysis for Idiopathic Pulmonary Fibrosis
Overview How likely is it that the drugs in Idiopathic Pulmonary Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Pulmonary Fibrosis Overview Idiopathic pulmonary fibrosis (IPF), or (formerly) fibrosing...
-
Product Insights
NewLikelihood of Approval Analysis for Obstructive Pulmonary Disease
Overview How likely is it that the drugs in Obstructive Pulmonary Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obstructive Pulmonary Disease Overview Chronic obstructive pulmonary disease (COPD) is a...
-
Product Insights
NewLikelihood of Approval Analysis for Pulmonary Arterial Hypertension
Overview How likely is it that the drugs in Pulmonary Arterial Hypertension will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Arterial Hypertension Overview Pulmonary arterial hypertension (PAH) is a type...
-
Product Insights
NewLikelihood of Approval Analysis for Chronic Obstructive Pulmonary Disease (COPD)
Overview How likely is it that the drugs in Chronic Obstructive Pulmonary Disease (COPD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chronic Obstructive Pulmonary Disease (COPD) Overview Chronic obstructive pulmonary...
-
Sector Analysis
NewTranscatheter Pulmonary Valve Replacement (TPVR) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
The Transcatheter Pulmonary Valve Replacement (TPVR) Market Report Overview The Transcatheter Pulmonary Valve Replacement (TPVR) market size was $44.6 million in 2023 and will drive the market growth at a CAGR of more than 8% from 2023 to 2033. Transcatheter heart valves are synthetic valves made from biological tissues surrounded by a steel, cobalt-chromium, or nitinol stent. There are two types of transcatheter heart valves: balloon expandable and self-expandable. One Transcatheter Heart Valve is referred to as a unit. TPVR...